학술논문
Compassionate Use of Remdesivir for Patients with Severe Covid-19
Original Article
Original Article
Document Type
Report
Author
Grein, Jonathan; Ohmagari, Norio; Shin, Daniel; Diaz, George; Asperges, Erika; Castagna, Antonella; Feldt, Torsten; Green, Gary; Green, Margaret L.; Lescure, Francois-Xavier; Nicastri, Emanuele; Oda, Rentaro; Yo, Kikuo; Quiros-Roldan, Eugenia; Studemeister, Alex; Redinski, John; Ahmed, Seema; Bernett, Jorge; Chelliah, Daniel; Chen, Danny; Chihara, Shingo; Cohen, Stuart H.; Cunningham, Jennifer; D'Arminio Monforte, Antonella; Ismail, Saad; Kato, Hideaki; Lapadula, Giuseppe; L'Her, Erwan; Maeno, Toshitaka; Majumder, Sumit; Massari, Marco; Mora-Rillo, Marta; Mutoh, Yoshikazu; Nguyen, Duc; Verweij, Ewa; Zoufaly, Alexander; Osinusi, Anu O.; DeZure, Adam; Zhao, Yang; Zhong, Lijie; Chokkalingam, Anand; Elboudwarej, Emon; Telep, Laura; Timbs, Leighann; Henne, Ilana; Sellers, Scott; Cao, Huyen; Tan, Susanna K.; Winterbourne, Lucinda; Desai, Polly; Mera, Robertino; Gaggar, Anuj; Myers, Robert P.; Brainard, Diana M.; Childs, Richard; Flanigan, Timothy
Source
The New England Journal of Medicine. June 11, 2020, Vol. 382 Issue 24, p2327, 10 p.
Subject
Language
English
ISSN
0028-4793
Abstract
Clinical improvement was observed in 36 of 53 severe Covid-19 patients (68%) who were treated with compassionate-use remdesivir. A 10-day course of remdesivir consisted of 200 mg administered intravenously on day 1, followed by 100 mg daily for the remaining 9 days of treatment. Ongoing randomized, placebo-controlled trials of remdesivir therapy will be required for measurement of efficacy.